AlphaFold identifies hundreds of thousands of new psychedelic molecules, potentially aiding antidepressant development, showcasing the tool's effectiveness in drug discovery compared to traditional experimental methods.
Tr1X , a new San Diego-based biotech, raises $75M to develop regulatory T cell (Treg) therapies for autoimmune conditions, planning to initiate multiple clinical trials later this year, focusing on graft-versus-host disease and inflammatory bowel disease.
Stuart Schreiber, co-founder of the Broad Institute, launches Arena BioWorks, a new research institution aimed at streamlining translational research from basic studies to drug development, funded by over $500 million from private financiers.
Insilico Medicine discovers novel AI-driven PHD inhibitor for anemia treatment using Chemistry42 AI platform, published in the Journal of Medicinal Chemistry.
S. Korea-based Mirae Asset Capital Life Science launches a $50M US biotech fund, focusing on oncology, immunology, cardiovascular, metabolic diseases, CNS, ophthalmology, and genetic diseases, including AI and machine learning tools for drug discovery.
CG Oncology sets IPO plans to raise up to $209M, focusing on advancing their bladder cancer treatment, cretostimogene.
Kyverna Therapeutics, developing novel CAR-T therapeutics for autoimmune diseases with their anti-CD19 CAR-T construct, is rumored to file for an IPO soon, advancing clinical trials for lupus nephritis, myasthenia gravis, and multiple sclerosis.
Myrobalan Therapeutics receives $24M in Series A funding to develop neurorestorative therapies targeting multiple sclerosis, Alzheimer’s, and other neurological conditions, focusing on GPCR antagonists, colony-stimulating factor-1 and TYK2 inhibitors to combat neuroinflammation.
S. Korean Pan Orion invests $415M in Korean biotech LegoChem Biosciences, becoming the largest shareholder. LegoChem, known for its ConjuALL technology in ADC therapies, collaborated also with J&J and Amgen, expanding Orion's foray into biopharmaceuticals.
Jaguar Gene Therapy creates Advanced Medicine Partners, a spinout specializing in manufacturing cell and gene therapies, showcasing expertise in adeno-associated virus production.
Taxes-based Enzolytics Inc partners with Khalpey AI Lab to advance organ regeneration and longevity research, leveraging AI for aging and organ failure analysis. They aim for novel biomarkers and therapeutic targets, focusing on multi-omic testing and AI algorithms in precision medicine.
Vivtex and AI Proteins enter a strategic R&D collaboration to develop novel, oral biologic therapies for inflammatory diseases, leveraging Vivtex’s GI-ORIS™ technology and AI Proteins’ miniprotein design to target TNFR1.
UK-based “tech-first” biotech CellVoyant has launched and raised £7.6 million in seed funding to speed up the development of novel cell therapies using AI.
AlphaFold identifies hundreds of thousands of new psychedelic molecules, potentially aiding antidepressant development, showcasing the tool's effectiveness in drug discovery compared to traditional experimental methods.
Tr1X , a new San Diego-based biotech, raises $75M to develop regulatory T cell (Treg) therapies for autoimmune conditions, planning to initiate multiple clinical trials later this year, focusing on graft-versus-host disease and inflammatory bowel disease.
S. Korea-based Mirae Asset Capital Life Science launches a $50M US biotech fund, focusing on oncology, immunology, cardiovascular, metabolic diseases, CNS, ophthalmology, and genetic diseases, including AI and machine learning tools for drug discovery.
CG Oncology sets IPO plans to raise up to $209M, focusing on advancing their bladder cancer treatment, cretostimogene.